Company* | Company* | Type/Product Area | Terms/Details (Date) |
| | |||
First Genetic Trust Inc.* | nTouch Research Corp.* | Alliance to advance the discovery and development of a new generation of pharmaceutical products matched to individual patients' genetic makeup | First Genetic's information technology operating system for genomic research and molecular medicine will be integrated with nTouch Research's biorepository of DNA samples (4/5) |
Genomics Collaborative Inc.* | AnVil Informatics Inc.* | Agreement to apply AnVil's analysis and visualization knowledge and tools to GCI's DNA microarray data | The project is designed to develop integrated visual analytic systems to identify gene expression patterns (4/24) |
Glaucus Proteomics BV* (the Netherlands) | SARA and GigaPort* (the Netherlands) | Agreements to provide the biocomputing capacity and connectivity to help Glaucus with the development of tools and technologies | The tools and technologies will be for high-throughput proteomic analysis and the screening of antibody and small-molecule drug candidates for improved specificity (4/24) |
Matritech Inc. (NMPS) | Bruker Daltonics Inc. (BDAL) | Partnership to develop an automated mass spectrometer system | The system would allow clinical laboratories to perform Matritech's proteomics-based cancer tests, including blood tests for breast and prostate cancer (5/20) |
Paracel Inc. (unit of Celera Genomics Group; NYSE:CRA) | Sun Microsystems Inc. (SUNW) | Paracel Transcript-Assembler and Paracel Genome-Assembler software | Agreement is to market the software on Sun platforms (3/12) |
Senomyx Inc.* | Nestle SA (Switzerland; Neuer Markt:NESZ) | Collaborative research and license agreement to discover and commercialize new ingredients to enhance taste of specified consumer food products | Nestle will provide research funding over a three-year period, as well as potential milestone payments and royalties (5/6) |
Senomyx Inc.* | The Coca-Cola Co. (NYSE:KO) | Agreement to research new flavors of soft drinks and other nonalcoholic beverages | Coca-Cola will pay Senomyx to conduct research and development in the field of flavor discovery; Senomyx must reach specific research goals and would receive royalties from the sale of any product that might use flavors it develops (5/7) |
Tensor Biosciences* | Matsushita Electric Industrial Co. Ltd. (Japan; NYSE:MC) | Five-year agreement to develop Brain-on-a-Chip drug discovery technology | The Brain-on-a-Chip platform is centered around the MED64 system developed by Matsushita; the drug-testing assays developed by Tensor will be patented by Matsushita and licensed exclusively back to Tensor for drug discovery (5/7) |
| | |||
Notes: | |||
# This chart does not include agreements that involve agricultural product development; chart includes one item before March 26 that was not listed in previous chart. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, the trading symbols listed for public companies are on the Nasdaq market. | |||
NYSE = New York Stock Exchange | |||
